KMDA
Kamada Ltd.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+7/100
Last price
8.06
▲ 0.06 (0.75%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
8.16
Prev close
8.00
Day high
8.26
Day low
7.86
Volume
146.65K
Market cap
$468.03M
P/E (TTM)
21.34
52W range
6.55 – 9.35
Day trading desk
Gap from prior close
+2.00%
Prior close 8.00
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
1.86%
8.06 – 8.21
Position in range
0%
Near session low
ATR (14D)
0.27
3.35% of price
Prior day high
8.13
PDH
Prior day low
7.93
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 116.75K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.78%
-8.7%
1M
-5.04%
-6.2%
3M
+11.40%
+6.9%
6M
-1.70%
-19.9%
YTD
+14.87%
+0.6%
1Y
+18.91%
+2.5%
3Y
+51.87%
-30.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KMDA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-81.00K
Net selling
Buy transactions
5
119.00K shares
Sell transactions
2
200.00K shares
Net transactions
+7
Buys less sells
Sell : buy shares
1.7 : 1
Mixed
Insider-held shares
4.05M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 14, 26 | LIVNEH NIR General Counsel |
CONVERSION | 10.00K | $53.70K | Direct |
| Sep 14, 26 | BRENNER YAEL Officer |
CONVERSION | 26.96K | $159.90K | Direct |
| Sep 14, 26 | TSUR DAVID Director |
SELL | 22.83K | $186.72K | Direct |
| Sep 9, 26 | TSUR DAVID Director |
SELL | 177.17K | $1.46M | Direct |
| Sep 2, 26 | TSUR DAVID Director |
CONVERSION | 49.00K | $328.69K | Direct |
| Sep 2, 26 | BRENNER YAEL Officer |
CONVERSION | 3.04K | $18.03K | Direct |
| Aug 26, 26 | BRENNER YAEL Officer |
CONVERSION | 30.00K | $187.50K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRENNER YAEL |
Officer | 6.27K | Conversion of Exercise of derivative security |
LIVNEH NIR |
General Counsel | 0 | Conversion of Exercise of derivative security |
TSUR DAVID |
Director | 407.93K | Sale |
Fundamentals
Market cap$468.03M
Enterprise value$411.14M
Revenue (TTM)$191.85M
Gross profit$78.31M
EBITDA$41.49M
Net income$22.25M
EPS (TTM)$0.38
Free cash flow$15.51M
Total cash$70.13M
Total debt$11.80M
Book value / share$4.66
Shares outstanding57.71M
Float33.18M
Short % of float0.51%
Dividend yield2.10%
Beta (5Y)0.13
Valuation & profitability ratios
Trailing P/E21.34
Forward P/E14.06
PEG ratio0.60
Price / sales—
Price / book1.74
EV / revenue2.14
EV / EBITDA9.91
Gross margin40.82%
Operating margin17.32%
Profit margin11.60%
Return on equity8.40%
Return on assets4.63%
Debt / equity4.38
Current ratio4.06
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $180.46M | $160.95M | $142.52M | $129.34M | +12.1% |
| Operating revenue | $180.46M | $160.95M | $142.52M | $129.34M | +12.1% |
| Cost of revenue | $104.05M | $90.99M | $87.03M | $82.64M | +14.4% |
| Gross profit | $76.41M | $69.97M | $55.49M | $46.70M | +9.2% |
| Research & development | $12.99M | $15.19M | $13.93M | $13.17M | -14.4% |
| Selling, general & admin | $33.84M | $30.83M | $27.45M | $25.06M | +9.8% |
| Total operating expense | $50.17M | $49.92M | $45.43M | $42.17M | +0.5% |
| Operating income | $26.23M | $20.05M | $10.06M | $4.53M | +30.8% |
| Net interest income | $1.06M | $1.46M | -$710.00K | -$823.00K | -27.5% |
| Pre-tax income | $23.47M | $13.33M | $8.43M | -$2.26M | +76.0% |
| Tax provision | $3.27M | -$1.13M | $145.00K | $62.00K | +389.8% |
| Net income | $20.20M | $14.46M | $8.28M | -$2.32M | +39.7% |
| Net income to common | $20.20M | $14.46M | $8.28M | -$2.32M | +39.7% |
| Basic EPS | 0.35 | 0.25 | 0.17 | -0.05 | +40.0% |
| Diluted EPS | 0.35 | 0.25 | 0.15 | -0.05 | +40.0% |
| EBIT | $24.33M | $13.99M | $9.73M | -$1.34M | +73.9% |
| EBITDA | $39.25M | $27.80M | $22.44M | $10.81M | +41.2% |
| Basic shares | 57.71M | 57.85M | 48.83M | 46.42M | -0.2% |
| Diluted shares | 57.71M | 57.85M | 53.68M | 46.42M | -0.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $75.47M | $78.44M | $55.64M | $34.26M | — | -3.8% |
| Cash & short-term investments | $75.47M | $78.44M | $55.64M | $34.26M | — | -3.8% |
| Accounts receivable | $27.01M | $21.39M | $19.73M | $27.13M | — | +26.3% |
| Inventory | $84.94M | $78.82M | $88.48M | $72.52M | — | +7.8% |
| Total current assets | $193.07M | $184.35M | $169.96M | $139.00M | — | +4.7% |
| Property, plant & equipment | $50.27M | $45.86M | $35.98M | $28.73M | — | +9.6% |
| Goodwill & intangibles | $126.41M | $132.17M | $139.96M | $147.01M | — | -4.4% |
| Total assets | $378.71M | $372.25M | $354.91M | $322.38M | — | +1.7% |
| Total current liabilities | $47.39M | $49.39M | $49.59M | $75.70M | — | -4.0% |
| Current debt | — | — | — | $4.44M | $2.63M | — |
| Long-term debt | — | — | — | $12.96M | $17.41M | — |
| Total debt | $11.56M | $11.06M | $8.82M | $20.60M | — | +4.5% |
| Total liabilities | $109.64M | $112.79M | $110.89M | $146.36M | — | -2.8% |
| Retained earnings | -$17.07M | -$25.74M | -$40.20M | -$48.48M | — | +33.7% |
| Shareholder equity | $269.07M | $259.46M | $244.02M | $176.02M | — | +3.7% |
| Working capital | $145.68M | $134.96M | $120.37M | $63.30M | — | +7.9% |
| Net tangible assets | $142.66M | $127.29M | $104.07M | $29.01M | — | +12.1% |
| Shares issued | 57.69M | 57.51M | 57.48M | 44.83M | — | +0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $20.20M | $14.46M | $8.28M | -$2.32M | +39.7% |
| Depreciation & amortisation | $14.92M | $13.81M | $12.71M | $12.15M | +8.0% |
| Stock-based compensation | $845.00K | $874.00K | $1.31M | $1.15M | -3.3% |
| Change in working capital | -$17.68M | $11.41M | -$18.20M | $11.65M | -254.9% |
| Operating cash flow | $25.49M | $47.59M | $4.32M | $28.59M | -46.4% |
| Capital expenditure | -$9.85M | -$10.74M | -$5.85M | -$3.78M | +8.3% |
| Investing cash flow | -$9.84M | -$10.74M | -$5.84M | -$3.78M | +8.4% |
| Dividends paid | -$11.53M | $0 | $0 | — | — |
| Financing cash flow | -$18.34M | -$13.91M | $22.68M | -$9.34M | -31.9% |
| Free cash flow | $15.64M | $36.85M | -$1.53M | $24.80M | -57.6% |
| End cash position | $75.47M | $78.44M | $55.64M | $34.26M | -3.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $54.92M | $45.24M | $44.68M | $47.01M | $44.75M | +21.4% |
| Operating revenue | $54.92M | $45.24M | $44.68M | $47.01M | $44.75M | +21.4% |
| Cost of revenue | $32.45M | $26.12M | $27.71M | $27.25M | $25.82M | +24.2% |
| Gross profit | $22.47M | $19.12M | $16.97M | $19.76M | $18.93M | +17.5% |
| Research & development | $2.20M | $2.18M | $2.89M | $2.64M | $3.22M | +0.9% |
| Selling, general & admin | $10.76M | $9.98M | $7.18M | $9.32M | $8.63M | +7.8% |
| Total operating expense | $12.96M | $12.16M | $13.42M | $11.95M | $11.86M | +6.5% |
| Operating income | $9.51M | $6.95M | $3.55M | $7.82M | $7.07M | +36.8% |
| Net interest income | $63.00K | $237.00K | $183.00K | $271.00K | $261.00K | -73.4% |
| Pre-tax income | $10.19M | $5.39M | $4.73M | $6.37M | $5.75M | +89.0% |
| Tax provision | $927.00K | $1.26M | $1.17M | $1.07M | -$1.62M | -26.4% |
| Net income | $9.26M | $4.13M | $3.56M | $5.30M | $7.38M | +124.2% |
| Net income to common | $9.26M | $4.13M | $3.56M | $5.30M | $7.38M | +124.2% |
| Basic EPS | 0.16 | 0.07 | 0.06 | 0.09 | 0.13 | +128.6% |
| Diluted EPS | 0.16 | 0.07 | 0.06 | 0.09 | 0.13 | +128.6% |
| EBIT | $10.56M | $5.58M | $4.99M | $6.59M | $5.95M | +89.3% |
| EBITDA | $14.45M | $9.43M | $8.79M | $10.35M | $9.69M | +53.2% |
| Basic shares | 57.89M | 59.03M | 59.37M | 58.84M | 56.74M | -1.9% |
| Diluted shares | 57.89M | 59.03M | 59.37M | 58.84M | 56.74M | -1.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $29.47M | $32.92M | $75.47M | $72.00M | $65.98M | — | -10.5% |
| Cash & short-term investments | $70.13M | $73.15M | $75.47M | $72.00M | $65.98M | — | -4.1% |
| Accounts receivable | $36.71M | $36.52M | $27.01M | $31.38M | $30.50M | — | +0.5% |
| Inventory | $86.88M | $85.44M | $84.94M | $85.41M | $82.08M | — | +1.7% |
| Total current assets | $199.57M | $199.24M | $193.07M | $192.73M | $183.27M | — | +0.2% |
| Property, plant & equipment | $52.00M | $50.37M | $50.27M | $47.29M | $47.14M | — | +3.2% |
| Goodwill & intangibles | $124.28M | $125.99M | $126.41M | $129.50M | $129.95M | — | -1.4% |
| Total assets | $383.16M | $383.02M | $378.71M | $377.21M | $368.17M | — | +0.0% |
| Total current liabilities | $49.16M | $59.78M | $47.39M | $47.84M | $45.77M | — | -17.8% |
| Total debt | $11.80M | $11.64M | $11.56M | $11.47M | $11.41M | — | +1.4% |
| Total liabilities | $113.60M | $123.63M | $109.64M | $111.98M | $108.22M | — | -8.1% |
| Retained earnings | -$18.10M | -$27.36M | -$17.07M | -$20.64M | -$25.93M | — | +33.8% |
| Shareholder equity | $269.56M | $259.39M | $269.07M | $265.23M | $259.95M | — | +3.9% |
| Working capital | $150.41M | $139.46M | $145.68M | $144.90M | $137.50M | — | +7.9% |
| Net tangible assets | $145.28M | $133.40M | $142.66M | $135.73M | $130.00M | — | +8.9% |
| Shares issued | 57.69M | 57.69M | 57.69M | 57.68M | — | 57.51M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $9.26M | $4.13M | $3.56M | $5.30M | $7.38M | +124.2% |
| Depreciation & amortisation | $3.89M | $3.85M | $3.80M | $3.76M | $3.75M | +1.0% |
| Stock-based compensation | $720.00K | $800.00K | $458.00K | $117.00K | $95.00K | -10.0% |
| Change in working capital | $3.77M | -$12.12M | -$482.00K | -$1.55M | -$3.22M | +131.1% |
| Operating cash flow | $18.07M | -$291.00K | $7.57M | $10.42M | $8.02M | +6,308.9% |
| Capital expenditure | -$2.11M | -$973.00K | -$2.77M | -$3.59M | -$2.01M | -116.5% |
| Investing cash flow | -$2.54M | -$41.20M | -$2.77M | -$3.59M | -$2.01M | +93.8% |
| Dividends paid | -$14.42M | $0 | $0 | $0 | -$11.53M | — |
| Financing cash flow | -$19.00M | -$856.00K | -$1.18M | -$754.00K | -$16.12M | -2,119.2% |
| Free cash flow | $15.96M | -$1.26M | $4.79M | $6.83M | $6.01M | +1,362.7% |
| End cash position | $29.47M | $32.92M | $75.47M | $72.00M | $65.98M | -10.5% |
Options analytics
Put / call volume
0.03
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
-69.2% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
32
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
7.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.11 | 0.16 | +42.2% |
| Mar 2026 | 0.12 | 0.07 | -39.1% |
| Dec 2025 | 0.08 | 0.06 | -22.6% |
| Sep 2025 | 0.09 | 0.09 | -2.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.13 | 4 | $157.40M | +2.6% |
| Next quarter | 0.12 | 4 | $150.80M | +9.6% |
| Current year | 0.48 | 4 | $608.52M | +9.5% |
| Next year | 0.58 | 3 | $685.40M | +12.6% |
Analyst targets & ownership
Mean target$13.50
High target$15.00
Low target$11.00
Implied upside67.49%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders6.99%
Held by institutions49.17%
Institutions holding74
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
8.47
-4.86% from price
SMA 20
8.43
-3.77% from price
SMA 50
8.02
+1.15% from price
SMA 100
7.70
+4.64% from price
SMA 200
7.99
+1.56% from price
EMA 12
8.37
-3.72% from price
EMA 26
8.33
-3.22% from price
EMA 50
8.13
-0.89% from price
RSI (14)
45.1
Neutral
MACD (12,26,9)
0.04
Hist -0.10
ATR (14)
0.27
3.33% of price
Realised vol 30D
37.1%
Annualised
Bollinger upper
9.07
20, 2σ
Bollinger lower
7.79
20, 2σ
50 / 200 cross
Golden
8.02 vs 7.99
Trend bias
Above 200
+1.56%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.02
More volatile than market
Correlation to SPY
0.38
Loosely linked
Realised vol 30D
37.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-26.1%
Peak to trough
Max drawdown 5Y
-44.4%
Peak to trough
ATR 14
0.27
3.33% of price
Beta (reported)
0.13
5Y monthly, from filing
Short interest
Shares short
160.82K
Prior 149.55K
Change vs prior
+7.5%
Shorts adding
% of float
0.51%
Normal
% of shares out
0.28%
Against total outstanding
Days to cover
0.9
Liquid
Float
33.18M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 15, 25 | Benchmark | MAINTAINED | Buy | Buy |
| Mar 21, 25 | Benchmark | INITIATED | — | Buy |
| Mar 6, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 10, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 14, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 3, 24 | Stifel | INITIATED | — | Buy |
| May 9, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 7, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 14, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 17, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate$0.17 / yr
Forward yield2.10%
5-year avg yield—
Payout ratio65.79%
Ex-dividend dateAug 27, 2026
Next pay dateSep 17, 2026
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-05
Corporate Changes & Voting Matters
6-K · 2026-09-17
Corporate Changes & Voting Matters
6-K · 2026-09-10
Offering Registrations
F-3 · 2026-09-09
Corporate Changes & Voting Matters
6-K · 2026-09-03
Corporate Changes & Voting Matters
6-K · 2026-08-17
Corporate Changes & Voting Matters
6-K · 2026-08-12
Corporate Changes & Voting Matters
6-K · 2026-08-05
Headlines
Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel
MT Newswires · 23h ago
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
GlobeNewswire · 24h ago
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth
MarketBeat · 10d ago
Kamada Maintains 'Sufficient' KedRAB Supply, Production Capacity Amid Increasing Rabies Exposures in US
MT Newswires · 20d ago
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
GlobeNewswire · 20d ago
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 27d ago
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
GlobeNewswire · 34d ago
Kamada (KMDA) Q2 2026 Earnings Call Transcript
Motley Fool · 49d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.